Please login to the form below

Not currently logged in
Email:
Password:

Novartis COPD drug delayed

The US Food and Drug Administration has pushed back making a decision on the marketing application for Novartis' QAB149 for chronic obstructive pulmonary disease by three months

The US Food and Drug Administration (FDA) has pushed back making a decision on the marketing application for Novartis' QAB149 (indacaterol) for chronic obstructive pulmonary disease (COPD) by three months.

Novartis said the FDA has not asked for additional data from the company, but needs the extra time to review data that has already been submitted. The agency now expects to take action on the application by July 2011.

"This three-month extension reflects discussion at the advisory committee based on the comprehensive clinical programme resulting in a large amount of data to be reviewed," said Trevor Mundel, global head of development at Novartis Pharma AG.

The FDA's Pulmonary-Allergy Drugs Advisory Committee, acting on a request from the FDA to evaluate the data for lower doses of QAB149, recently voted 13 to four in favour of recommending approval of a 75mcg dose, but 12 to five against recommending approval of a 150mcg dose.

The committee members deemed the lower dose as effective as the higher one and determined that the data showed that both doses are safe.

The advisory committee made its recommendations after reviewing five phase III clinical trials in which the efficacy of QAB149 at 75 and 150mcg was studied in a total of 1,282 COPD patients. The data showed that both doses significantly improved lung function compared to placebo, beginning five minutes after the first dose and lasting for 24 hours.

QAB149 was submitted for US regulatory approval in December 2008. In late 2009, the FDA issued a complete response letter declining to approve the drug until Novartis provided additional information on the proposed dosing.

Novartis is seeking US approval of the once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with COPD including chronic bronchitis and/or emphysema. The product is already approved in dozens of countries around the world under the brandname Onbrez Breezhaler.

24th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics